Table 3 |
||
|
Summary of the Strengths and Limitations of Ovarian Cancer Immunotherapy |
||
|
Strategies |
Pros |
Cons |
|
|
||
|
Antibody-based vaccine |
Tumor antigen specific. Easy to produce. |
Weak immunogenicity. Not for all individuals. |
|
Peptide vaccine |
Safe, stable, and easy to produce and modify. |
Poor immunogenicity. HLA restriction. |
|
Cytokine vaccine |
Easy to manufacture and administer. |
Non-specific immunomodulating only. |
|
Tumor cell vaccine |
Convenience, contained tumor antigen pool. |
Potential safety concern. Difficult to produce. Difficult to standardize. |
|
Dendritic cell vaccine |
Powerful professional antigen presenting cells. May prime both T cells and antibody response. |
Difficult to manufacture and standardize. |
|
HSP vaccine |
May contain multiple antigens. |
Difficult to manufacture and standardize. |
|
Immunomodulation with Treg blockage |
Promising strategy |
No data on ovarian cancer yet Difficult to completely eliminate Treg. |
|
|
||
|
Liu et al. Journal of Hematology & Oncology 2010 3:7 doi:10.1186/1756-8722-3-7 |
||
